secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2023-09-05T23:59:59+00:00
Accession:  0001437749-23-025203
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CMO Kirsten Gruis resigns; interim CMO Jordan Dubow appointed for stroke trial
------------------------------------------------------------------------------

- CMO Kirsten Gruis resigned effective Aug 31, 2023; she will consult for 9 months at $33,500/month.
- Jordan Dubow, M.D., vascular neurologist with extensive CMO experience, engaged as interim CMO.
- Dr. Dubow to accelerate site engagement and enrollment in Phase 2/3 ReMEDy2 trial of DM199 for acute ischemic stroke.
- Dr. Dubow has served as CMO for eight companies and worked on 16 NDAs through FDA's Division of Neurology.
- Separation agreement includes standard non-disparagement and confidentiality; no severance as resignation was voluntary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774923025203/0001437749-23-025203-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774923025203/dmtp20230903_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-025203

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer